AI-generated analysis. Always verify with the original filing.
Vertex Pharmaceuticals Incorporated reported consolidated financial results for Q4 and full year 2025, with total revenue of $3.19 billion (up 10% YoY) and $12.0 billion (up 9% YoY), respectively, driven by CF therapies and diversification. The company provided FY 2026 total revenue guidance of $12.95 to $13.1 billion, including $500 million or more from non-CF products.
Event Type
Disclosure
Mandatory
Variant
8-K
. Results of Operations and Financial Condition. On February 12, 2026, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it re
. Financial Statements and Exhibits. (d) Exhibits Exhibit Description of Document 99.1 Press Release Dated February 12 , 202 6 . 104 Cover Page Interactive Data
| Metric | Value | Basis |
|---|---|---|
| Total Revenue | $3.19 | |
| Total Revenue | $12.00 | |
| Combined GAAP R&D, Acquired IPR&D and SG&A Expenses | $1.52 | GAAP |
| Combined GAAP R&D, Acquired IPR&D and SG&A Expenses | $1.36 | Non-GAAP |
| GAAP Net Income | $1.20 | GAAP |
| Non-GAAP Net Income | $1.30 | Non-GAAP |
| Combined GAAP R&D, Acquired IPR&D and SG&A Expenses | $5.80 | GAAP |
| Combined GAAP R&D, Acquired IPR&D and SG&A Expenses | $5.10 | Non-GAAP |
| GAAP Net Income | $4.00 | GAAP |
| Non-GAAP Net Income | $4.70 | Non-GAAP |